PDS Biotechnology (PDSB) Share-based Compensation (2014 - 2026)
PDS Biotechnology's (PDSB) quarterly Share-based Compensation came in at $3.9 million in Q4 2025, up 137.39% YoY from $1.6 million in Q4 2024, and up 213.13% on a QoQ basis from $1.2 million in Q3 2025.
PDS Biotechnology (PDSB) Share-based Compensation (2014 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Share-based Compensation data on file, last reported at $3.9 million in Q4 2025.
- Quarterly Share-based Compensation rose 137.39% year-over-year to $3.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.8 million (down 15.29% YoY) and the FY2025 annual result came in at $6.3 million, down 40.38% from the prior year.
- Share-based Compensation advanced to $3.9 million in Q4 2025, from $1.2 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $3.9 million in Q4 2025 to a low of -$5.2 million in Q4 2023.
- A 5-year average of $710274.6 and a median of $1.2 million in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2021 — Share-based Compensation soared 1211.15% — and 2022, when it plunged 312.19%.
- Tracing PDSB's Share-based Compensation over 5 years: stood at $1.7 million in 2021, then sank by 312.19% to -$3.6 million in 2022, then tumbled by 47.52% to -$5.2 million in 2023, then soared by 131.39% to $1.6 million in 2024, then jumped by 137.39% to $3.9 million in 2025.
- The last three Share-based Compensation figures came in at $3.9 million (Q4 2025), $1.2 million (Q3 2025), and $448029.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - | 1.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.13 Mn |
| Jun 30, 2026 | 1.13 Mn |
| Dec 31, 2025 | 3.90 Mn |
| Dec 31, 2025 | 3.90 Mn |
| Sep 30, 2025 | 1.25 Mn |
| Sep 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 448,029.00 |
| Jun 30, 2025 | 448,029.00 |
| Mar 31, 2025 | 203,501.00 |
| Mar 31, 2025 | 203,501.00 |
| Dec 31, 2024 | 1.64 Mn |
| Dec 31, 2024 | 1.64 Mn |
| Sep 30, 2024 | 1.78 Mn |
| Sep 30, 2024 | 1.78 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Mar 31, 2024 | 1.63 Mn |
| Mar 31, 2024 | 1.63 Mn |
| Dec 31, 2023 | -5.24 Mn |
| Dec 31, 2023 | -5.24 Mn |